The estimated Net Worth of Robert Langer is at least $915 Million dollars as of 28 April 2022. Robert Langer owns over 703 units of Moderna Inc stock worth over $911,793,965 and over the last 20 years he sold MRNA stock worth over $2,407,280. In addition, he makes $500,000 as Non-Executive Independent Director at Moderna Inc.
Robert has made over 21 trades of the Moderna Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 703 units of MRNA stock worth $55,896 on 28 April 2022.
The largest trade he's ever made was selling 200,000 units of Moderna Inc stock on 13 April 2012 worth over $480,000. On average, Robert trades about 16,955 units every 96 days since 2004. As of 28 April 2022 he still owns at least 11,467,664 units of Moderna Inc stock.
You can see the complete history of Robert Langer stock trades at the bottom of the page.
Dr. Robert Langer serves as Non-Executive Independent Director of the Company. Dr. Langer has been an Institute Professor at MIT since 2005, and prior to that was a Professor at MIT beginning in 1977. Dr. Langer currently serves on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY), Kala Pharmaceuticals, Inc. (Nasdaq: KALA), and the UK public company Puretech Health plc (LON: PRTC), and previously served on the board of directors of Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), Wyeth (NYSE: WYE), Fibrocell Science, Inc. (Nasdaq: FCSC) and Millipore Corporation (acquired by Merck KGaA in 2010). Dr. Langer also served as a member of the Science Board to the U.S. Food and Drug Administration from 1995 to 2002, including his service as chairman from 1999 to 2002. Dr. Langer received his B.S. from Cornell University and his Sc.D. from MIT, both in Chemical Engineering.
As the Non-Executive Independent Director of Moderna Inc, the total compensation of Robert Langer at Moderna Inc is $500,000. There are 13 executives at Moderna Inc getting paid more, with Stephane Bancel having the highest compensation of $8,948,210.
Robert's mailing address filed with the SEC is C/O SEER, INC., 3800 BRIDGE PARKWAY, REDWOOD CITY, CA, 94065.
Over the last 6 years, insiders at Moderna Inc have traded over $2,713,086,305 worth of Moderna Inc stock and bought 52,631 units worth $999,989 . The most active insiders traders include Noubar Afeyan, David M. Rubenstein, and Stephane Bancel. On average, Moderna Inc executives and independent directors trade stock every 2 days with the average trade being worth of $2,841,687. The most recent stock trade was executed by Shannon Thyme Klinger on 6 September 2024, trading 1,139 units of MRNA stock currently worth $90,562.
moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a
Moderna Inc executives and other stock owners filed with the SEC include: